stockrow
Friday 6 November 2026
Export COCH’s income statement to Excel — free account
Envoy Medical, Inc.
COCH Healthcare Medical Devices
Envoy Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $241,000.00, up 7.11% from fiscal 2024.
- Revenue
- +57.1%
- EPS
- −42.9%
- Free cash flow
- −22.4%
Quarter to September 2026, against a year earlier
7.19
0.09
+1.27%
Follow COCH
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 4 | 4 | — |
| 184.92% | 400.01% | 214.32% | 564.62% | ||
| (285.25%) | (139.91%) | (168.14%) | (189.84%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
674.72% | (171.16%) | (278.88%) | 193.43% | |
Average Days of Receivables |
80.27 | 74.87 | 116.38 | 107.45 | |
Free Cash Flow per Share |
(7.90) | (2.98) | (2.09) | — | |
Free Cash Flow |
(18.38) | (20.54) | (21.71) | — | |
Capital Expenditures |
(0.18) | — | (0.18) | — | |
| Other line items | |||||
Cash ROIC |
218.32% | (57.99%) | (94.47%) | 0.00% | |
Accounts Receivable Turnover |
0.55 | 4.14 | 3.21 | 3.79 | |
Accounts Payable Turnover |
0.38 | 0.57 | 0.55 | 0.49 | |
Inventory Turnover |
0.54 | 0.61 | 0.63 | 0.66 | |
Average Days of Payables |
1,219.45 | 645.68 | 739.08 | 552.39 | |
Days of Inventory on Hand |
645.64 | 565.92 | 573.47 | 526.91 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
5,180.91% | 5,717.95% | 6,776.33% | 6,235.50% | |
Selling, General and Administrative Expense of Revenue |
3,797.10% | 3,852.56% | 4,249.28% | 0.00% | |
Share Based Compensation of Revenue |
309.13% | 370.94% | 467.63% | 0.00% | |
Interest Coverage |
(14.01) | — | — | — | |
Operating CF/Net income |
0.64 | 0.73 | 0.76 | 0.00 | |
Depreciation/Fixed assets |
1.22 | 1.31 | 1.34 | 0.00 | |
Capex/Depreciation |
(0.14) | 0.00 | (0.14) | — | |
Revenue per Share |
0.10 | 0.03 | 0.02 | 0.00 | |
Operating CF per Share |
(7.82) | (2.98) | (2.07) | — | |
Capex per Share |
(0.08) | 0.00 | (0.02) | — | |
Capex to Sales |
0.74 | 0.00 | 0.86 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026